drugset / Trial / NCT06237205
Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency
Phase 2
Not yet recruiting
33 enrolled
Korea University Anam Hospital
Korean Cancer Study Group · collabTakeda · collab
NaSingle-groupOpen-labelTreatment
Summary
Investigational Products: Niraparib Period: 3 years after IRB/EC approval Indication: Adult patients with histologically confirmed and locally advanced, unresectable, or metastatic solid tumors having known or suspected deleterious mutations in genes involved in homologous recombination repair (HRR) or homologous recombination deficiency identified by whole genome sequencing
Timeline
- Start
- 2024-02-27
- Primary completion
- 2026-06-30
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Niraparib | Small molecule | — | — |
Indications
No indication recorded.